参附强心丸治疗心力衰竭的研究进展  

Research progress on the treatment of heart failure with Shenfu Qiangxin pill

作　　者：朱海云[1] 李婷[2] 吴颍东 邓芳隽 陈磊[2] Zhu Haiyun;Li Ting;Wu Yingdong;Deng Fangjuan;Chen Lei(Department of Cardiovascular Medicine,Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital,Tianjin 300120,China;Tianjin University of Traditional Chinese Medicine,Tianjin 301617,China)

机构地区：[1]天津市中医药研究院附属医院心血管内科,天津300120 [2]天津中医药大学,天津301617

出　　处：《中国中西医结合急救杂志》2024年第4期504-507,共4页Chinese Journal of Integrated Traditional and Western Medicine in Intensive and Critical Care

基　　金：天津市中医药重点领域科研项目(2024015);郭利平天津市名中医传承工作室(2024-03-14)。

摘　　要：心力衰竭(心衰)具有复杂的病理生理机制和高病死率及再住院率,其作为心血管疾病的终末期表现和最主要的死亡原因一直是医学界关注的焦点.尽管西医在心衰的标准化治疗上已取得显著进展,但仍有大量患者面临心血管事件的高风险.参附强心丸作为治疗心衰的代表性中成药之一,近年来在其作用机制研究及临床应用方面取得了诸多成效.本文从中西医对心衰的认识、参附强心丸的组方与功效、参附强心丸的研究进展与机制探讨、参附强心丸的临床应用与安全性方面阐述参附强心丸治疗心衰的最新研究动态,展示其在心衰治疗中的潜力和应用前景,为心衰的临床治疗提供理论依据.Heart failure(HF)has complex pathophysiological mechanisms and is associated with high mortality and readmission rates.As the terminal manifestation of cardiovascular disease and the main cause of death,HF remains a critical focus in the medical community.Despite advances in standardized treatment through western medicine,many patients remain at high risk for cardiovascular events.Shenfu Qiangxin pill,a traditional Chinese patent medicine,has shown promising results in recent years regarding its mechanisms and clinical applications for HF treatment.This article elaborates on the latest research trends of Shenfu Qiangxin pill in the treatment of HF,examining its composition,efficacy,and mechanisms from both traditional Chinese and western medical perspectives.It also explores its clinical applications and safety,highlighting its potential and prospects in HF treatment and providing a theoretical basis for clinical practice.

关 键 词：参附强心丸 心力衰竭 研究进展 

分 类 号：R541.6[医药卫生—心血管疾病]